Angiotensin Receptor Blockers (ARBs) Global Market Report 2025

Description

Angiotensin receptor blockers (ARBs) are medications designed to widen blood vessels, addressing conditions such as high blood pressure (hypertension), heart failure, and kidney disease, particularly in individuals with diabetes. These drugs work by blocking the effects of angiotensin, a chemical in the body that causes blood vessels to constrict, leading to increased blood pressure and added strain on the heart.

The primary products within the class of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan, and olmesartan. Losartan, for instance, is an ARB that not only treats hypertension but also reduces the risk of stroke and manages diabetic nephropathy. These medications find applications in various medical conditions, such as hypertension, cardiovascular diseases, kidney diseases, among others, and are utilized by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The angiotensin receptor blockers (ARBs) market research report is one of a series of new reports from The Business Research Company that provides angiotensin receptor blockers (ARBs) market statistics, including angiotensin receptor blockers (ARBs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (ARBs) market share, detailed angiotensin receptor blockers (ARBs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (ARBs) industry. This angiotensin receptor blockers (ARBs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angiotensin receptor blockers (ARBs) market size has grown steadily in recent years. It will grow from $8.51 billion in 2024 to $8.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to hypertension epidemic, clinical efficacy, cardiovascular disease burden, renal protection, clinical guidelines, ARBs as first-line treatment, cost-effectiveness.

The angiotensin receptor blockers (ARBs) market size is expected to see steady growth in the next few years. It will grow to $10.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to precision medicine approaches, focus on combination therapies, global expansion of market, biomarker-based treatment strategies, government initiatives, increased awareness of hypertension. Major trends in the forecast period include telemedicine adoption, research and development investments, generic competition and patent expirations, digital health solutions for medication adherence, biosimilar competition.

The rising incidence of chronic kidney diseases is anticipated to drive the growth of the angiotensin receptor blockers (ARBs) market in the coming years. Chronic kidney disease (CKD) is a long-term condition marked by the gradual decline of kidney function over time. Angiotensin receptor blockers are utilized in managing CKD by lowering blood pressure, providing renal protection, addressing diabetic nephropathy, and managing cardiovascular complications. For instance, in June 2023, a report from the University of Oxford, a UK-based higher education institution, indicated that the prevalence of CKD is expected to increase by 4% from 8.27 million to 8.61 million people in the UK between 2022 and 2032. Therefore, the rising prevalence of chronic kidney diseases is fueling the growth of the angiotensin receptor blockers market.

The growing prevalence of hypertension is also expected to drive the growth of the angiotensin receptor blockers (ARBs) market in the future. Hypertension, commonly referred to as high or elevated blood pressure, is characterized by persistently high pressure in the blood vessels. ARBs are a category of medication frequently prescribed for hypertension, working by relaxing and widening blood vessels to facilitate smoother blood flow. As the incidence of hypertension increases among the population, so will the demand for angiotensin receptor blockers. For instance, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 1.28 billion adults aged 30 to 79 worldwide have hypertension, with two-thirds residing in low- and middle-income countries. It is estimated that 46% of adults with hypertension are unaware of their condition. Additionally, in December 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that more than one in ten individuals (11.6% or 3.0 million) in 2022 indicated having hypertension. Consequently, the rising prevalence of hypertension is driving the growth of the angiotensin receptor blockers (ARBs) market.

The escalating prevalence of hypertension diseases is poised to drive the expansion of the angiotensin receptor blockers (ARBs) market in the foreseeable future. Hypertension, characterized by persistently elevated blood pressure, finds treatment through medications such as angiotensin receptor blockers (ARBs), which operate by widening blood arteries, facilitating smoother blood flow. This increased prevalence of hypertension among the populace is expected to heighten the demand for angiotensin receptor blockers. For instance, data from the Centers for Disease Control and Prevention (CDC) in July 2023 highlighted hypertension as a leading cause of mortality in the US, accounting for 691,095 fatalities in 2021. Approximately 47% of US adults, totaling 116 million individuals, suffer from hypertension, with only 24% having it under control. An estimated 34 million individuals recommended medication may necessitate prescription initiation, emphasizing the substantial demand for treatment. This data underscores how the rising prevalence of hypertension diseases is fueling the growth of the angiotensin receptor blockers (ARBs) market.

Major companies in the angiotensin receptor blocker market are focused on developing advanced products, such as angiotensin receptor neprilysin inhibitors, to improve treatment options and enhance outcomes for patients with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) are a category of medications used for heart failure treatment. For example, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched sacubitril + valsartan tablets specifically designed for heart failure, particularly targeting heart failure with reduced ejection fraction (HFrEF). This combination falls under the ARNI class of medications. Sacubitril enhances the natriuretic peptide (NP) system, helping to relieve fluid overload and promote vasodilation, while valsartan inhibits the renin-angiotensin system (RAS) to reduce blood pressure and lessen the heart's workload. Together, these medications effectively alleviate heart failure symptoms, lower the risk of cardiovascular mortality, and decrease the likelihood of hospitalization due to heart failure. They are marketed under the brand name Sacu V.

Major companies operating in the angiotensin receptor blockers (ARBs) market are advancing the development of prescription medications to enhance the treatment of conditions such as hypertension and heart failure while improving patient outcomes. Prescription medications are drugs that can only be legally dispensed to patients when prescribed by a licensed healthcare professional, including doctors, nurse practitioners, or dentists. For instance, in July 2022, Lupin, an India-based transnational pharmaceutical company, received approval from the Food and Drug Administration (FDA), a US federal agency responsible for public health protection, for Azilsartan Medoxomil Tablets. Azilsartan Medoxomil Tablets are a prescription medication primarily used for treating hypertension (high blood pressure). They serve as an effective treatment option for hypertension, aiding in blood pressure reduction and decreasing the risk of cardiovascular events. This medication belongs to the angiotensin II receptor blocker (ARB) class, working by relaxing blood vessels to facilitate easier blood flow, thus helping to lower blood pressure. Reducing blood pressure contributes to the prevention of strokes, heart attacks, and kidney issues.

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the angiotensin receptor blockers (arbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Angiotensin Receptor Blockers (ARBs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angiotensin receptor blockers (arbs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angiotensin receptor blockers (arbs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The angiotensin receptor blockers (arbs) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Valsartan; Telmisartan; Losartan; Irbesartan; Azilsartan; Olmesartan
2) By Application: Hypertension; Cardiovascular Diseases; Kidney Diseases; Other Applications
3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets; Capsules; Injectable Forms
2) By Telmisartan: Tablets; Capsules
3) By Losartan: Tablets; Oral Solution
4) By Irbesartan: Tablets; Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets; Oral Suspension
Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca Plc.; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23140

1. Executive Summary

2. Angiotensin Receptor Blockers (ARBs) Market Characteristics

3. Angiotensin Receptor Blockers (ARBs) Market Trends And Strategies

4. Angiotensin Receptor Blockers (ARBs) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Angiotensin Receptor Blockers (ARBs) Growth Analysis And Strategic Analysis Framework

5.1. Global Angiotensin Receptor Blockers (ARBs) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Angiotensin Receptor Blockers (ARBs) Market Growth Rate Analysis
5.4. Global Angiotensin Receptor Blockers (ARBs) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Angiotensin Receptor Blockers (ARBs) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Angiotensin Receptor Blockers (ARBs) Total Addressable Market (TAM)

6. Angiotensin Receptor Blockers (ARBs) Market Segmentation

6.1. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
6.2. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other Applications
6.3. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
6.4. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Valsartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Injectable Forms
6.5. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Telmisartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
6.6. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Losartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Oral Solution
6.7. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Irbesartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Oral Solution
6.8. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Azilsartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
6.9. Global Angiotensin Receptor Blockers (ARBs) Market, Sub-Segmentation Of Olmesartan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Oral Suspension

7. Angiotensin Receptor Blockers (ARBs) Market Regional And Country Analysis

7.1. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market

8.1. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Angiotensin Receptor Blockers (ARBs) Market

9.1. China Angiotensin Receptor Blockers (ARBs) Market Overview
9.2. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Angiotensin Receptor Blockers (ARBs) Market

10.1. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Angiotensin Receptor Blockers (ARBs) Market

11.1. Japan Angiotensin Receptor Blockers (ARBs) Market Overview
11.2. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Angiotensin Receptor Blockers (ARBs) Market

12.1. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Angiotensin Receptor Blockers (ARBs) Market

13.1. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Angiotensin Receptor Blockers (ARBs) Market

14.1. South Korea Angiotensin Receptor Blockers (ARBs) Market Overview
14.2. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Angiotensin Receptor Blockers (ARBs) Market

15.1. Western Europe Angiotensin Receptor Blockers (ARBs) Market Overview
15.2. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Angiotensin Receptor Blockers (ARBs) Market

16.1. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Angiotensin Receptor Blockers (ARBs) Market

17.1. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Angiotensin Receptor Blockers (ARBs) Market

18.1. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Angiotensin Receptor Blockers (ARBs) Market

19.1. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Angiotensin Receptor Blockers (ARBs) Market

20.1. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market

21.1. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market Overview
21.2. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Angiotensin Receptor Blockers (ARBs) Market

22.1. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Angiotensin Receptor Blockers (ARBs) Market

23.1. North America Angiotensin Receptor Blockers (ARBs) Market Overview
23.2. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Angiotensin Receptor Blockers (ARBs) Market

24.1. USA Angiotensin Receptor Blockers (ARBs) Market Overview
24.2. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Angiotensin Receptor Blockers (ARBs) Market

25.1. Canada Angiotensin Receptor Blockers (ARBs) Market Overview
25.2. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Angiotensin Receptor Blockers (ARBs) Market

26.1. South America Angiotensin Receptor Blockers (ARBs) Market Overview
26.2. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Angiotensin Receptor Blockers (ARBs) Market

27.1. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Angiotensin Receptor Blockers (ARBs) Market

28.1. Middle East Angiotensin Receptor Blockers (ARBs) Market Overview
28.2. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Angiotensin Receptor Blockers (ARBs) Market

29.1. Africa Angiotensin Receptor Blockers (ARBs) Market Overview
29.2. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape And Company Profiles

30.1. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape
30.2. Angiotensin Receptor Blockers (ARBs) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca Plc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Angiotensin Receptor Blockers (ARBs) Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Teva Pharmaceutical Industries Ltd.
31.3. Daiichi Sankyo Company Limited
31.4. Lupin Limited
31.5. Dr. Reddy's Laboratories Ltd.
31.6. Takeda Pharmaceutical Company Limited
31.7. Thermo Fisher Scientific
31.8. Sanofi
31.9. Johnson & Johnson
31.10. Eli Lilly
31.11. Bayer AG
31.12. Abbvie Inc.
31.13. Mylan N.V.
31.14. Sun Pharmaceutical Industries Ltd.
31.15. Torrent Pharmaceuticals Ltd.

32. Global Angiotensin Receptor Blockers (ARBs) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Angiotensin Receptor Blockers (ARBs) Market

34. Recent Developments In The Angiotensin Receptor Blockers (ARBs) Market

35. Angiotensin Receptor Blockers (ARBs) Market High Potential Countries, Segments and Strategies

35.1 Angiotensin Receptor Blockers (ARBs) Market In 2029 - Countries Offering Most New Opportunities
35.2 Angiotensin Receptor Blockers (ARBs) Market In 2029 - Segments Offering Most New Opportunities
35.3 Angiotensin Receptor Blockers (ARBs) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer